If you have not yet heard much about Digital therapeutics (DTx), they are a new category of medical interventions that leverage high-quality software programs to prevent, manage, or treat a medical disorder or disease. Sounds like general health or wellness apps we have been seeing a lot recently?
The difference is DTx products are evidence-based, meaning their effectiveness is backed by rigorous clinical trials and they often require regulatory clearance (similar to traditional medical devices or pharmaceuticals).
They can be delivered through various digital platforms like smartphone apps, wearable devices, virtual reality, or web-based programs. DTx can function as standalone therapies or complement existing treatments, empowering patients to manage their conditions, promote behavioral changes, and improve health outcomes in a personalized and accessible way.
In other words, the future of healthcare.
Japan’s DTx Roster:
In October 2019, a study identified seven companies actively producing Digital Therapeutics (DTx) in Japan, playing a key role in the nascent but growing market. These foundational companies have significantly influenced the industry’s expansion. Currently, over 40 companies are estimated to be actively developing DTx in Japan, with many more involved in research and development for various diseases. Although only a few DTx products have received medical approval and are commercially available, extensive research and development efforts are underway across numerous companies.
Imposing arguably the most influence on the Japanese DTx market is CureApp.
Japan’s leading DTx company helps treat hypertension by educating patients and promoting healthy lifestyle changes between doctor visits. Their digital therapeutic solution aims to empower patients to manage their condition more effectively, leading to improved health outcomes and reduced reliance on medication. CureApp is dedicated to revolutionizing healthcare through technology, aiming to make high-quality treatment universally accessible. CureApp is also actively developing therapeutic apps for a variety of conditions, including NASH, alcohol addiction, various cancers, chronic heart failure, and chronic low back pain, demonstrating their commitment to addressing diverse healthcare needs.
On the other hand, Sumitomo Pharma specializes in chronic conditions, particularly mental health and active aging, across Japan and the US. They are actively developing VR-based digital therapeutics (DTx) in collaboration with RealizedCare for social anxiety, generalized anxiety, and major depressive disorders, intended to be prescribed alongside behavioral therapies. Additionally, they are conducting a clinical study for a mobile app designed for type 2 diabetes management, developed with Save Medical. Sumitomo Pharma is dedicated to increasing DTx accessibility and incorporating digital solutions into global healthcare, with a primary focus on mental health, diabetes, and pediatric ophthalmology.
While some companies achieve remarkable success, others face significant hurdles in business expansion and client acquisition. This begs the question: what makes growth so challenging for them, especially in Japan, and what is needed to overcome these obstacles? Given that Japan is relatively new to DTx compared to the US, what are the essential elements for DTx to flourish in the Japanese market?
What does DTx need to thrive in Japan?
Japan is rapidly emerging as a significant player in the global digital therapeutics (DTx) landscape, leveraging its advanced technology and a pressing need to address the challenges of an aging population. However, the full potential of DTx in Japan hinges on overcoming several key hurdles:
-
-
-
- One major challenge lies in establishing clearer and more predictable reimbursement pathways. Currently, only a limited number of DTx products have secured national health insurance coverage, making it difficult for developers to project profitability and plan their businesses effectively. A streamlined and transparent framework, akin to those for traditional pharmaceuticals and medical devices, is crucial to incentivize further innovation and investment in the sector.
-
- Regulatory processes need to be continuously refined and case studies accumulated. While the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) are actively working to clarify approval procedures, more precedents and guidance are needed, particularly for clinical trial planning and managing software modifications after approval.
-
- Robust data infrastructure, privacy, and interoperability are also critical. Challenges persist in collecting, storing, and sharing electronic medical records seamlessly, and ensuring secure cross-border data flows while protecting patient privacy is paramount. Investing in standardized electronic medical record systems and legislation to facilitate responsible data exchange will be essential.
-
- To truly foster growth, Japan needs a stronger ecosystem and enhanced industry collaboration. The number of domestic DTx companies is still relatively small, and fostering partnerships among startups, established firms, academia, and government will accelerate research, development, and commercialization. Initiatives like the Japan Digital Therapeutics Consortium and international collaborations, especially with the US and Europe, are vital for sharing best practices.
-
- Expanded insurance coverage and equitable access are also high priorities. Limited insurance coverage can lead to disparities in access, particularly in rural and underserved areas. Expanding coverage and exploring innovative financing models, such as development impact bonds, could help ensure DTx benefits reach all who need them.
-
- Finally, public and professional education are crucial for broader adoption. Raising awareness and understanding of DTx among healthcare providers and the general public about its benefits, safety, and efficacy will be key to integrating these innovative solutions into mainstream healthcare. As AI and advanced technologies increasingly integrate with DTx, developing and adopting responsible AI and data governance frameworks is also vital to ensure ethical and safe innovation.
-
-
The Potential Growth of DTx in Japan
If Japan’s digital therapeutics (DTx) market can provide solutions to the above, and there is no reason it can’t given time, it will certainly accelerate the robust growth it is already starting to experience, driven by an urgent need for innovative healthcare solutions in the face of its rapidly aging population – 29.3% of the Japanese population are aged 65 or older, the highest globally. Valued at approximately USD 319.5 million in 2024, the overall DTx market is projected to skyrocket to USD 1.92 billion by 2033. The prescription digital therapeutics (PDTx) segment is poised for even more dramatic expansion, with forecasts indicating a leap from USD 35.23 billion in 2024 to an estimated USD 259.99 billion by 2032.
This impressive trajectory is further fueled by the integration of advanced technologies like AI, machine learning, virtual reality (VR), and augmented reality (AR), which enhance the personalization and effectiveness of DTx.
While Japan’s Digital Therapeutics (DTx) market is still nascent compared to the more mature landscape of the United States, the building blocks are there for Japan to be a significant global player in digital health solutions. Overcoming hurdles in reimbursement, regulatory clarity, data infrastructure, and fostering stronger ecosystem collaboration will be crucial for DTx to fully flourish in Japan. We are definitely bookmarking in this space that DTx is poised to revolutionize healthcare delivery, offering personalized and accessible solutions that enhance patient outcomes and contribute to a more sustainable healthcare system.
Article written by Kunal Mistry – Titan Consulting Business Operations Intern